Pembrolizumab in endometrial cancer: Where we stand now (Review)
- Authors:
- Aikaterini Aravantinou‑Fatorou
- Angeliki Andrikopoulou
- Michael Liontos
- Oraianthi Fiste
- Vasiliki E. Georgakopoulou
- Meletios-Athanasios Dimopoulos
- Maria Gavriatopoulou
- Flora Zagouri
-
Affiliations: First Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens 11527, Greece, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece - Published online on: October 8, 2021 https://doi.org/10.3892/ol.2021.13082
- Article Number: 821
-
Copyright: © Aravantinou‑Fatorou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, et al ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group, : ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Dowdy SC: Improving oncologic outcomes for women with endometrial cancer: Realigning our sights. Gynecol Oncol. 133:370–374. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Miller D, Filiaci V, Fleming G, Mannel R, Cohn D, Matsumoto T, Tewari K, DiSilvestro P, Pearl M and Zaino R: Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 125:7712012. View Article : Google Scholar |
|
Fleming GF: Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant. J Clin Oncol. 25:2983–2990. 2007. View Article : Google Scholar : PubMed/NCBI |
|
Morice P, Leary A, Creutzberg C, Abu-Rustum N and Darai E: Endometrial Cancer. 387:1094–1108. 2016.PubMed/NCBI |
|
Markman M: Hormonal therapy of endometrial cancer. Eur J Cancer. 41:673–675. 2005. View Article : Google Scholar : PubMed/NCBI |
|
Moxley KM and McMeekin DS: Endometrial carcinoma: A review of chemotherapy, drug resistance, and the search for new agents. Oncologist. 15:1026–1033. 2010. View Article : Google Scholar : PubMed/NCBI |
|
Bourla AB and Zamarin D: Immunotherapy: New strategies for the treatment of gynecologic malignancies. Oncology (Williston Park). 30:59–66, 69. 2016.PubMed/NCBI |
|
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM and Zarour HM: IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res. 75:1635–1644. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 4:127ra372012. View Article : Google Scholar : PubMed/NCBI |
|
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK and Iyer AK: PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 8:5612017. View Article : Google Scholar : PubMed/NCBI |
|
Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI |
|
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Herzog TJ, Arguello D, Reddy SK and Gatalica Z: PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy. Gynecol Oncol. 137:204–205. 2015. View Article : Google Scholar |
|
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al Cancer Genome Atlas Research Network, : Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI |
|
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J and Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. In: Journal of clinical epidemiology. J Clin Epidemiol. s62:e1–34. 2009. View Article : Google Scholar : PubMed/NCBI |
|
Therkildsen C, Jensen LH, Rasmussen M and Bernstein I: An update on immune checkpoint therapy for the treatment of lynch syndrome. Clin Exp Gastroenterol. 14:181–197. 2021. View Article : Google Scholar : PubMed/NCBI |
|
Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, García de Santiago B and Casado Sáenz E: Immune checkpoint inhibitors in endometrial cancer. Crit Rev Oncol Hematol. 161:1033062021. View Article : Google Scholar : PubMed/NCBI |
|
Mo DC, Luo PH, Huang SX, Wang HL and Huang JF: Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. Int Immunopharmacol. 91:1072812021. View Article : Google Scholar : PubMed/NCBI |
|
Oaknin A, León-Castillo A and Lorusso D: Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): Data and perspectives. Curr Opin Oncol. 32:471–480. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Musacchio L, Boccia SM, Caruso G, Santangelo G, Fischetti M, Tomao F, Perniola G, Palaia I, Muzii L, Pignata S, et al: Immune checkpoint inhibitors: A promising choice for endometrial cancer patients? J Clin Med. 9:17212020. View Article : Google Scholar : PubMed/NCBI |
|
Green AK, Feinberg J and Makker V: A Review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 40:1–7. 2020.PubMed/NCBI |
|
Rubinstein MM and Makker V: Optimizing immunotherapy for gynecologic cancers. Curr Opin Obstet Gynecol. 32:1–8. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Sobecki-Rausch J and Barroilhet L: Anti-programmed Death-1 immunotherapy for endometrial cancer with microsatellite instability-high tumors. Curr Treat Options Oncol. 20:832019. View Article : Google Scholar : PubMed/NCBI |
|
Grywalska E, Sobstyl M, Putowski L and Roliński J: Current possibilities of gynecologic cancer treatment with the use of immune checkpoint inhibitors. Int J Mol Sci. 20:202019. View Article : Google Scholar |
|
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K and Veneris JL: Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 69:258–279. 2019.PubMed/NCBI |
|
Pan K, Gong J, Huynh K and Cristea M: Current systemic treatment landscape of advanced gynecologic malignancies. Target Oncol. 14:269–283. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Barrington DA, Dilley SE, Smith HJ and Straughn JM Jr: Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecol Oncol. 153:381–384. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Richardson DL: New and novel therapies for gynecologic cancers. Semin Oncol Nurs. 35:217–219. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Garcia C and Ring KL: The role of PD-1 checkpoint inhibition in gynecologic malignancies. Curr Treat Options Oncol. 19:702018. View Article : Google Scholar : PubMed/NCBI |
|
Arend RC, Jones BA, Martinez A and Goodfellow P: Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecol Oncol. 150:569–580. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Makker V, Green AK, Wenham RM, Mutch D, Davidson B and Miller DS: New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 4:192017. View Article : Google Scholar : PubMed/NCBI |
|
Mittica G, Ghisoni E, Giannone G, Aglietta M, Genta S and Valabrega G: Checkpoint inhibitors in endometrial cancer: Preclinical rationale and clinical activity. Oncotarget. 8:90532–90544. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Tomao F, Panici PB and Tomao S: Pembrolizumab in programmed death ligand 1-positive endometrial cancer. J Clin Oncol. 35:36332017. View Article : Google Scholar : PubMed/NCBI |
|
Danley K, Schmitz K, Ghai R, Sclamberg JS, Buckingham LE, Burgess K, Kuzel TM and Usha L: A durable response to pembrolizumab in a patient with uterine serous carcinoma and lynch syndrome due to the MSH6 germline mutation. Oncologist. May 20–2021.(Epub ahead of print). doi: 10.1002/onco.13832. View Article : Google Scholar |
|
Carvalho JP, Del Giglio A, Achatz MI and Carvalho FM: Complete clinical response in stage IVB endometrioid endometrial carcinoma after first-line pembrolizumab therapy: Report of a case with isolated loss of PMS2 protein. Case Rep Oncol. 13:1067–1074. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Ramos A, Del Carmen M and Yeku O: PD-1 inhibitor therapy in a patient with preexisting P-ANCA vasculitis: A case report and review of the literature. Case Rep Oncol Med. 2020:34289452020.PubMed/NCBI |
|
Chan JK, Lakomy DS, McDonald Y and Kapp DS: Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer. Gynecol Oncol Rep. 33:1005812020. View Article : Google Scholar : PubMed/NCBI |
|
Takeda A, Koike W and Watanabe K: Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review. Gynecol Oncol Rep. 32:1005532020. View Article : Google Scholar : PubMed/NCBI |
|
Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, et al: Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 153:471–478. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Dizon DS, Dias-Santagata D, Bregar A, Sullivan L, Filipi J, DiTavi E, Miller L, Ellisen L, Birrer M and DelCarmen M: Complete remission following pembrolizumab in a woman with mismatch repair-deficient endometrial cancer and a germline BRCA1 mutation. Oncologist. 23:650–653. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, et al: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. J Clin Oncol. 35:2535–2541. 2017. View Article : Google Scholar : PubMed/NCBI |
|
Choi MC, Moon YW, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim G and Kim KA: Real-world experience with pembrolizumab treatment in patients with heavily treated recurrent gynecologic malignancies. Yonsei Med J. 61:844–850. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Roque DM, Bellone S, Siegel ER, Buza N, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, et al: A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). J Clin Oncol. 39 (Suppl 15):5523. 2021. View Article : Google Scholar |
|
How J: The use of pembrolizumab and lenvatinib combination therapy in endometrial cancer. An examination of toxicity and treatment efficacy in clinical practice Presented at: The virtual 2021 SGO Annual Meeting on Womens Cancer; March 19–25, 2021, . Abstract 10775. |
|
Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, et al: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 38:2981–2992. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 38:1–10. 2020. View Article : Google Scholar : PubMed/NCBI |
|
Fader AN, Diaz LA, Armstrong DK, Tanner EJ III, Uram J, Eyring A, Wang H, Fisher G, Greten T and Le D: Preliminary results of a phase II study: PD-1 blockade in mismatch repair-deficient, recurrent or persistent endometrial cancer. Gynecol Oncol. 141:206–207. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Makker V: A multicenter, open-label, randomized, phases III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer. Abstract ID: 11512. Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women's Cancer. March 19-25–2021. |
|
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI |
|
O'Malley D, Marabelle A, De Jesus-Acosta A, Piha-Paul SA, Arkhipov A, Longo F, Motola-Kuba D, Shapira-Frommer R, Geva R, Rimel BJ, et al: Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study. Ann Oncol. 30:v425–v426. 2019. View Article : Google Scholar |
|
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al KEYNOTE-006 investigators, : Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al KEYNOTE-189 investigators, : pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI |
|
Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T and Asada M: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 122:664–671. 2008. View Article : Google Scholar : PubMed/NCBI |
|
Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M and Funahashi Y: Antitumor activity of lenvatinib (E7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014:6387472014. View Article : Google Scholar : PubMed/NCBI |
|
Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M and Tsuruoka A: Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 340:97–103. 2013. View Article : Google Scholar : PubMed/NCBI |
|
ClinicalTrials.gov. Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9/MK-7902-001) (LEAP-001). ClinicalTrials.gov Identifier: NCT03884101. https://www.clinicaltrials.gov/ct2/show/NCT03884101June 16–2021 |
|
ClinicalTrials.gov. Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 MK-7902-001). China Extension Study (LEAP −001). ClinicalTrials.gov Identifier: NCT04865289. https://clinicaltrials.gov/ct2/show/NCT04865289June 16–2021 |
|
Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, et al: The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 4:137–144. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, et al: Combining radiation and immunotherapy: A new systemic therapy for solid tumors? Cancer Immunol Res. 2:831–838. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 203:1259–1271. 2006. View Article : Google Scholar : PubMed/NCBI |
|
ClinicalTrials.gov. Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer. ClinicalTrials.gov Identifier: NCT04214067. https://clinicaltrials.gov/ct2/show/NCT04214067June 16–2021 |
|
Patel SP and Kurzrock R: PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Mukherji D, Jabbour MN, Saroufim M, Temraz S, Nasr R, Charafeddine M, Assi R, Shamseddine A and Tawil AN: Programmed death-ligand 1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: A reliable treatment selection biomarker? Clin Genitourin Cancer. 14:183–187. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Schlötterer C: Evolutionary dynamics of microsatellite DNA. Chromosoma. 109:365–371. 2000. View Article : Google Scholar : PubMed/NCBI |
|
Murali R, Soslow RA and Weigelt B: Classification of endometrial carcinoma: More than two types. Lancet Oncol. 15:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI |
|
Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I and Church DN: A panoply of errors: Polymerase proofreading domain mutations in cancer. Nat Rev Cancer. 16:71–81. 2016. View Article : Google Scholar : PubMed/NCBI |
|
Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, Lopez S, Bonazzoli E, Predolini F, Ferrari F, et al: Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 138:11–17. 2015. View Article : Google Scholar : PubMed/NCBI |
|
Uryvaev A, Passhak M, Hershkovits D, Sabo E and Bar-Sela G: The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol. 35:252018. View Article : Google Scholar : PubMed/NCBI |
|
Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX and Xu RH: Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 5:1504–1506. 2019. View Article : Google Scholar : PubMed/NCBI |
|
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr, et al: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365. 2020. View Article : Google Scholar : PubMed/NCBI |